02Jul 2022
Glucagon‐like peptide‐1 effect on β‐cell function varies according to diabetes remission status after Roux‐en‐Y gastric bypass

Glucagon‐like peptide‐1 effect on β‐cell function varies according to diabetes remission status after Roux‐en‐Y gastric bypass

The contribution of endogenous glucagon‐like peptide (GLP)‐1 to β‐cell function after Roux‐en‐Y gastric bypass surgery (RYGB) is well established in normoglycaemic individuals, but not in those with postoperative hyperglycaemia. Therefore, studied the effect of GLP‐1 on β‐cell function in individuals with varying degrees of type 2 diabetes mellitus (T2D) control after RYGB. GLP‐1 blockade reversed the improvement in β‐cell function observed after RYGB, but this effect varied temporally and by REM status. GLP‐1 blockade transiently and minimally worsened glycaemia only in REM, and lowered postprandial glucose values at 3 months, regardless of REM status.

  • #endo-diabetology

Like

Save

Share